Literature DB >> 26085886

CUA-CUOG CRPC Guidelines: A useful compendium.

Joseph L Chin1.   

Abstract

Year:  2015        PMID： 26085886      PMCID： PMC4455646          DOI： 10.5489/cuaj.2873

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  3 in total

1.  Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.

Authors:  Ivan Jambor; Anna Kuisma; Susan Ramadan; Riikka Huovinen; Minna Sandell; Sami Kajander; Jukka Kemppainen; Esa Kauppila; Joakim Auren; Harri Merisaari; Jani Saunavaara; Tommi Noponen; Heikki Minn; Hannu J Aronen; Marko Seppänen
Journal:  Acta Oncol       Date:  2015-04-02       Impact factor: 4.089

2.  CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.

Authors:  Fred Saad; Sebastien Hotte; Charles Catton; Darrel Drachenberg; Antonio Finelli; Neil Fleshner; Martin Gleave; Anil Kapoor; Wassim Kassouf; Andrew Loblaw; Scott North; Nawaid Usmani; Kim N Chi
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

3.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.